Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Matt Phipps has maintained a Buy rating on Context Therapeutics (CNTX) stock, citing promising developments in the CTIM-76 study. Preliminary data from the Phase Ia study showed early antitumor activity, particularly in a patient with platinum-resistant ovarian cancer. The study reported no severe cytokine release syndrome or dose-limiting toxicities, indicating a favorable safety profile. Piper Sandler also issued a Buy rating with a $4.00 price target on the same day, reinforcing the positive outlook for the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments